Chemical and Physical Characterization of Serum Albumin Nanocarriers and Applications in Nanomedicine
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Macromolecular Chemistry".
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 1994
Special Issue Editors
Interests: molecular imaging; radiopharmacology; internal radiotherapy; intraoperative detection; diagnostic oncology
Special Issues, Collections and Topics in MDPI journals
Interests: radiopharmaceuticals; radioactive tracers; nuclear medicine radiolabeling; new PET imaging radionuclides
Special Issues, Collections and Topics in MDPI journals
Interests: radiobiology; hadrontherapy; migration; cell biology; cell signalling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Since 2005, a tremendous increase in published papers related to albumin nanocolloid or nanoparticles has occurred, with approximately 900 articles in these fields being published annually in Pub Med. Bovine serum albumin (BSA) is the most widely used serum due to its low cost, abundance and easy purification, whereas human serum albumin (HSA) is used to prevent immunological responses.
Albumin is a versatile protein carrier extensively used for drug delivery, and albumin-based nanocarriers are proven to enhance the biostability and bioavailability of many compounds, maintaining a safe and efficient delivery.
Albumin is specifically used to target tumor tissue, essentially through two mechanisms. The first mechanism is passive and is related to enhanced penetration and retention, which is less effective in humans compared to rodents. The second mechanism is active and targets obtained loading recognition ligands to achieve a specific binding to target cells and selective drug delivery.
These approaches are not just limited to oncological applications; other fields of medicine are involved, such as vaccines, infectious diseases and many others.
HSA nanocolloids were and are extensively used in nuclear medicine for sentinel lymph node detection; beyond 99mTc, other nuclides, such as PET emitters and non-radioactive labels, have been proposed, including fluorescent and optoacoustic signals in a multimodality approach. HSA nanocarriers loaded with recognition ligands and nuclides for imaging and internal radiotherapy are the new frontier for this kind of theranostic agent.
Dr. Carlo Aprile
Dr. Lorenzo Lodola
Dr. Angelica Facoetti
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- albumin nanocarriers
- HSA nanocolloids
- nanomedicine
- theranostic agent
- Nano HSA, molecular imaging
- radiolabeled nanoparticles
